Navigation Links
GEN reports on recent progress in Alzheimer's research
Date:8/7/2012

New Rochelle, NY, August 7, 2012The global market value of Alzheimer's disease therapeutics could soar to the $8 billion range once therapeutics are approved that actually change the course of the disease, reports Genetic Engineering & Biotechnology News (GEN). The current therapeutic market is valued at $3 to $4 billion, shared among drugs that temporarily delay disease progression or address the symptoms but do not alter the underlying disease, according to a recent issue of GEN.

"Despite all the research on amyloid plaques and neurofibrillary tangles there is still a debate on whether these biological phenomena are causative or symptomatic of Alzheimer's," said John Sterling, Editor-in-Chief of GEN. "Once scientists can clearly and unequivocally define key factors related to the actual biology of the disease itself, therapeutic advances could take place much more quickly."

More than 150 companies are working in the Alzheimer's space, including approximately 15 multinationals and 30 generics companies. A number of these firms are taking innovative approaches to tackling this extremely debilitating disease. For example, the USPTO in March granted a patent for Antisenilin, developed by Intellect Neurosciences. This therapy, which targets either end of -amyloid, is in Phase III trials.

Baxter has a Phase III program under way for Gammagard, a naturally occurring plasma-derived immunoglobulin for moderate-stage AD patients. The trial runs until February 2013. Phase II results suggest Gammagard may positively affect brain atrophy and cognition. The compound already is approved for immunodeficiency diseases.

Other companies covered in the GEN article include AstraZeneca, Roche, TransTech Pharma, Astex Pharmaceuticals, Memory Pharmaceuticals, Sanofi-Aventis, Eli Lill
'/>"/>

Contact: John Sterling
jsterling@genengnews.com
914-740-2196
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Page: 1 2

Related biology news :

1. BGI reports the latest finding on NMNAT1 mutations linked to Leber congenital amaurosis
2. Aware, Inc. Reports Second Quarter 2012 Financial Results
3. GEN reports on growth of tissue engineering revenues
4. BGI reports the completed sequence of foxtail millet genome
5. Radiologists study necessity of additional imaging recommendations in PET/CT oncologic reports
6. Aware, Inc. Reports First Quarter 2012 Financial Results
7. From 503-million-year-old fungi to recent earthquakes: New Geology posted ahead of print
8. House funding bill will delay research progress and place new burdens on NIH
9. Guam conservation efforts progress
10. New report evaluates progress of Everglades Restoration Plan
11. Progress in Osteoporosis re-launched with new design, now invites commentary
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
GEN reports on recent progress in Alzheimer's research
(Date:7/30/2014)... figured out how to create colors, nature had already ... of many different hues, for example. Now scientists are ... friendly way to make colored plastics. Their paper on ... materials rather than dyes, to produce color appears ... N. Asger Mortensen, Anders Kristensen and colleagues point out ...
(Date:7/30/2014)... of Engineering recently received a $330,000 award from ... synthesis of organic nanorods." , According to ... and utilization of functional materials, devices, and systems ... in scaling up nanotechnology is the lack of ... one device. A research team led by Dr. ...
(Date:7/30/2014)... spinal cord injury (SCI), traumatic brain injury (TBI) and ... has been learned over the past 30 years regarding ... regulate axon growth, but this large body of information ... Lemmon and his team from University of Miami in ... but a consensus is emerging that one contributing factor ...
Breaking Biology News(10 mins):NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... YORK, N.Y. Cornell University and the United Nations University ... health, governance and security of the African continent when it ... Nov. 13. The series is free and open to the ... will be Africas food system and its interactions with health ...
... Hospital of Pittsburgh of UPMC are participating in an international ... insulin in preventing or delaying the onset of type 1 ... researchers want to determine if one insulin capsule taken daily ... in relatives of people who are found to be at ...
... Human Genome Sciences, Inc. (Nasdaq: HGSI) today ... demonstrating that LymphoStat-B (belimumab) achieved a sustained improvement ... the frequency of disease flares over time, and ... in combination with standard of care in patients ...
Cached Biology News:First symposium of UN University-Cornell Africa Series to be held at UN 2Children's Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes 2HGS announces positive Phase 2 LymphoStat-B at ACR meeting 2HGS announces positive Phase 2 LymphoStat-B at ACR meeting 3HGS announces positive Phase 2 LymphoStat-B at ACR meeting 4
(Date:7/30/2014)... CA (PRWEB) July 30, 2014 ... presentations of leading Immunologists, Principle Investigators, scientists in ... Charles J Malemud, Professor at Case Western Reserve ... delivering his keynote address on “The effects ... in production of matrix metalloproteinase-9”. Arya Biragyn, a ...
(Date:7/29/2014)... 30, 2014 “PharmaSphere: Emerging Biotech ... Venture Capital Funding” report provides in-depth analysis of ... equity and venture capital segments of the financial ... to have significant impact on the future of ... Furthermore, the report identifies regions of the world ...
(Date:7/29/2014)... DIEGO , July 29, 2014   Sequenom, ... sciences company that provides innovative genetic analysis solutions, and ... of esoteric laboratory services in the United ... noninvasive prenatal testing patents and applications. "We ... innovation, and patient care, and we welcome the opportunity ...
(Date:7/29/2014)... (July 29, 2014) Tough, ultralight foam of atom-thick ... through a chemical process invented at Rice University. ... like a nanoscale building, with floors and walls that ... of two-dimensional materials: floors and walls of graphene oxide ... platelets. , The researchers say the foam could ...
Breaking Biology Technology:Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4Tough foam from tiny sheets 2
... Texas , May 13 U.S. Renal Care, Inc. ... that it is extending its previously announced cash tender offer, through ... shares of common stock of Dialysis Corporation of America (Nasdaq: ... City time, on June 1, 2010 , unless further ...
... , May 13 /PRNewswire-Asia/ -- A signing ceremony for ... (TJAB) and Genzyme Corporation was held in the,Tianjin Economic-Technological Development Area ... , , ... Zihe, President of TJAB and,President of Nankai University, He Shushan, Director ...
... Texas , May 13 Sergio Lopez , 18, of ... marrow-derived stem cells in lieu of traditional surgery to repair a broken bone ... as a non-union, is to implant a device, such as a screw or ... , , ...
Cached Biology Technology:U.S. Renal Care, Inc. Announces Extension of Tender Offer for Dialysis Corporation of America 2U.S. Renal Care, Inc. Announces Extension of Tender Offer for Dialysis Corporation of America 3Tianjin International Joint Academy of Biotechnology and Medicine, Genzyme Enter into Strategic Partnership 2Texas Teen Opts for Stem Cell Therapy, Hopes of Enlisting in Military 2Texas Teen Opts for Stem Cell Therapy, Hopes of Enlisting in Military 3
... reagent has been developed for use ... reduction of nonspecific background staining due ... describe blocking peroxidase with hydrogen peroxide. ... in combination with additional novel components ...
Rabbit polyclonal to Wilms Tumor Protein ( Abpromise for all tested applications). entrezGeneID: 7490 SwissProtID: P19544...
Ku80 Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Request Info...
Biology Products: